The AI engine is offline (last seen Aug 12, 05:02 UTC). Scores are shown as of their timestamps; new theses and refreshes are queued and run the moment it returns.

Macro

Search catalysts, news stories, and pressures, or browse the trust-weighted news feed below.

Home tech energy finance healthcare defense industrial consumer communication utilities real estate raw materials
← back
healthcare · sector mood
2019
year mood +0.04 · -0.10 to +0.10 across 12 mo
Monthly mood
bearish −1 +1 bullish
-0.25 -0.12 0 +0.12 +0.25 Jan Feb +0.10 Mar Apr May -0.10 Jun Jul Aug Sep Oct Nov Dec
month values ▾
JanFebMarAprMayJunJulAugSepOctNovDec
+0.04+0.10+0.10+0.00-0.10+0.09+0.00+0.00+0.00+0.10+0.10+0.10

Medicare-for-All fear during the Democratic primary crushed insurers and hospitals mid-year, while pharma stayed steady; the fear eased in the autumn as moderate Biden rose over Warren.

How this mood is scored ▾
Each day the model reads that day's news for the sector and asks, as someone who owns assets or makes their living in it: how am I feeling this month, and why? The month's mood is that running answer, tied to the specific events driving it (the story shown above). It leans on trusted, higher-impact reporting, and on the prior month when a month is quiet, so one loud headline can't swing it. The read updates daily through the month; once a month ends, its mood is locked. This year is read live from the news the pipeline actually collected (hover a bar for its story count). · last computed Jul 11, 2026
Top healthcare stories of 2019
Jan
Bristol-Myers to acquire Celgene in $74B megadeal cnbc.com →

Bristol-Myers Squibb is acquiring Celgene in a $74 billion cash-and-stock transaction, creating a combined oncology-focused pharmaceutical giant amid investor skepticism and a significant increase in debt. The deal aims to bolster Bristol's declining immuno-oncology portfolio and address Celgene's looming patent expirations, particularly for Revlimid. Market reaction was mixed, with Bristol's shares falling 12% and credit default swaps spiking, reflecting concerns over valuation and long-term growth prospects.

Jun
AbbVie to acquire Allergan for $63 billion to diversify beyond Humira biospace.com →

AbbVie is acquiring Allergan in a $63 billion cash-and-stock deal to reduce reliance on its flagship drug Humira and gain scale in new therapeutic areas like aesthetics and neuroscience. The transaction is expected to be immediately accretive, enhancing AbbVie’s growth platform while maintaining its U.S. headquarters and leadership structure.